AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 18 - (NewsRx.com & NewsRx.net) -- Organon, Inc. has announced that it received U.S. Food and Drug Administration (FDA) approval to market NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), the first monthly vaginal ring for birth control.
NuvaRing is a flexible, transparent ring that provides month-long contraceptive protection and can be discretely administered by a woman in the privacy of her own home. The product works by releasing a continuous low dose of estrogen and progestin, on average 0.120 mg of etonogestrel and 0.015 mg of ethinyl estradiol, per day over a 21 day period of use.
"Women are always searching for more convenient contraceptive options. Like the pill, NuvaRing is effective yet is administered only once a month and gives women more freedom and allows them to be spontaneous. Women using NuvaRing won't have to think about their birth control everyday, but can be confident about their protection," said Dr. Larry Seidman, Clinical Assistant Professor, Obstetrics and Gynecology, MCP - Hahnemann School of Medicine in Philadelphia ...
Source: HighBeam Research, First Monthly Vaginal Ring Receives FDA Approval.